Caring Ambassadors Hepatitis C

Program Newsletter

CA_logo-bluewww.HepCChallenge.org

January 2011

Clinical Trials, Cohort Studies, Pilot Studies

Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. Martinez AD, Dimova R, Marks KM, et al. J Viral Hepat. 2010 Dec 3. doi: 10.1111/j.1365-2893.2010.01411.x. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21129131

Hepatitis C virus-related kidney disease: various histological patterns. Sumida K, Ubara Y, Hoshino J, et al. Clin Nephrol. 2010 Dec;74(6):446-56.
http://www.ncbi.nlm.nih.gov/pubmed/21084048

Early Menopause is Associated with Lack of Response to Antiviral Therapy in Women with Chronic Hepatitis C. Villa E, Karampatou A, Cammà C, et al. Gastroenterology. 2010 Dec 15. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21167831

Increasing Prevalence of HCC and Cirrhosis in Patients with Chronic Hepatitis C Virus Infection. Kanwal F, Hoang T, Kramer JR, et al. Gastroenterology. 2010 Dec 21. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21184757

Hepatitis C virus and alcohol: Same mitotic targets but different signaling pathways.
Alisi A, Ghidinelli M, Zerbini A, Missale G, Balsano C. J Hepatol. 2010 Dec 21. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21145809

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.
Oze T, Hiramatsu N, Yakushijin T, et al. J Hepatol. 2010 Dec 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21145907

The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort. Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT. Dig Dis Sci. 2010 Dec 7. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21136163

Glucose control and lipid metabolism in African American patients with type 2 diabetes and chronic hepatitis C. Zambare S, Samantray J, Seyoum B, Abou-Samra AB. Endocr Pract. 2010 Dec 6:1-19. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21134881

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy). Halfon P, Pérusat S, Bourlière M, et al. J Med Virol. 2010 Dec;82(12):2027-31.
http://www.ncbi.nlm.nih.gov/pubmed/20981789

Hepatitis C virus infection and increased risk of cerebrovascular disease. Lee MH, Yang HI, Wang CH, et al. Stroke. 2010 Dec;41(12):2894-900. Epub 2010 Oct 21.
http://www.ncbi.nlm.nih.gov/pubmed/20966408

Development and Progression of Portal Hypertensive Gastropathy in Patients With Chronic Hepatitis C. Fontana RJ, Sanyal AJ, Ghany MG, et al. Am J Gastroenterol. 2010 Dec 7. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21139575

Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon α-2b and ribavirin. Devitt EJ, Power KA, Lawless MW, et al. Eur J Gastroenterol Hepatol. 2010 Dec 15. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21164346

Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Gupta SK, Kolz K, Cutler DL. Eur J Clin Pharmacol. 2010 Dec 16. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21161196

A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients. Lawson A; on behalf of the Trent Hepatitis C Study Group. J Viral Hepat. 2010 Dec 7. doi: 10.1111/j.1365-2893.2010.01406.x. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21138506

Basic and Applied Science, Pre-Clinical Studies

Dynamic coinfection with multiple viral subtypes in acute hepatitis C. Smith JA, Aberle JH, Fleming VM, et al. J Infect Dis. 2010 Dec 15;202(12):1770-9. Epub 2010 Nov 10.
http://www.ncbi.nlm.nih.gov/pubmed/21067369

Reactivation of Epstein-Barr virus in B cells of patients with chronic hepatitis C.
Shimozuma Y, Ito T, Inokuchi M, Uchikoshi M, et al. J Med Virol. 2010 Dec;82(12):2064-72.
http://www.ncbi.nlm.nih.gov/pubmed/20981794

Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist. Tajuddin T, Ryan EJ, Norris S, Hegarty JE, O'Farrelly C. J Gastroenterol Hepatol. 2010 Dec;25(12):1883-90. doi: 10.1111/j.1440-1746.2010.06281.x.
http://www.ncbi.nlm.nih.gov/pubmed/21092001

Characterization of the specific CD4+ T cell response against the F protein during chronic hepatitis C virus infection. Gao DY, Jin GD, Yao BL, et al. PLoS One. 2010 Dec 6;5(12):e14237.
http://www.ncbi.nlm.nih.gov/pubmed/21151917

Coinfection

Changing Rate of Non-B Subtypes and Coinfection with Hepatitis B/C Viruses in Newly Diagnosed HIV Type 1 Individuals in Spain. Treviño A, Soriano V, Rodríguez C, et al. AIDS Res Hum Retroviruses. 2010 Dec 6. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21039316

Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on metha-done maintenance therapy. Taylor LE, Bowman SE, Chapman S, et al.
http://www.ncbi.nlm.nih.gov/pubmed/21177046

Chronic immune activation in the T cell compartment of HCV/HIV-1 co-infected patients.
Sandberg JK, Falconer K, Gonzalez VD. Virulence. 2010 Dec 22;1(3):177-9.
http://www.ncbi.nlm.nih.gov/pubmed/21178437

Plasma cytokine concentrations associated with HIV/hepatitis C coinfection are related to attention, executive and psychomotor functioning. Cohen RA, de la Monte S, Gongvatana A, et al. J Neuroimmunol. 2010 Dec 9. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21146232

Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B poly-morphism in HIV/HCV co-infected patients. de Araújo ES, Dahari H, Cotler SJ, et al. J Acquir Immune Defic Syndr. 2010 Dec 13. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21157362

Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Woreta TA, Sutcliffe CG, Mehta SH, et al. Gastroenterology. 2010 Dec 3. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21134375

Acute hepatitis C in HIV-infected individuals - recommendations from the NEAT consensus conference. Rockstroh JK; The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. AIDS. 2010 Dec 6. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21139491

Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Thomson EC, Fleming VM, Main J, et al. Gut. 2010 Dec 7. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21139063

Impact of liver steatosis on the correlation between liver stiffness and fibrosis measured by transient elastography in patients coinfected with human immunodeficiency virus and hepatitis C virus. Sánchez-Conde M, Montes Ramírez ML, Bellón Cano JM, et al. J Viral Hepat. 2010 Dec 3. doi: 10.1111/j.1365-2893.2010.01407.x. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21129129

Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Taylor LE, Bowman SE, Chapman S, et al. Drug Alcohol Depend. 2010 Dec 20. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21177046

An Interrupted Time Series Evaluation of a Hepatitis C Intervention for Persons with HIV.
Proeschold-Bell RJ, Hoeppner B, Taylor B, Cohen S, Blouin R, Stringfield B, Muir AJ. AIDS Behav. 2010 Dec 30. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21191643

Complementary and Alternative Medicine

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. Lange CM, Bojunga J, Ramos-Lopez E, et al. J Hepatol. 2010 Dec 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21145801

Vitamins B status and antioxidative defense in patients with chronic hepatitis B or hepatitis C virus infection. Lin CC, Liu WH, Wang ZH, Yin MC. Eur J Nutr. 2010 Dec 24. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21184088

Interferon plus Chinese herbs are associated with higher sustained virological response than interferon alone in chronic Hepatitis C: A meta-analysis of randomised trials. Zhao S, Liu E, Wei K, et al. Antiviral Res. 2010 Dec 15. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21167210

Association Of Caffeine Intake and Histological Features of Chronic Hepatitis C. Costentin CE, Roudot-Thoraval F, Zafrani ES, et al. J Hepatol. 2010 Dec 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21145804

Dietary History and Physical Activity and Risk of Advanced Liver Disease in Veterans with Chronic Hepatitis C Infection. White DL, Richardson PA, Al-Saadi M, et al. Dig Dis Sci. 2010 Dec 28. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/21188525

Epidemiology, Diagnostics, and Miscellaneous Works

Injection practices among clinicians in United States health care settings. Pugliese G, Gosnell C, Bartley JM, Robinson S. Am J Infect Control. 2010 Dec;38(10):789-98.
http://www.ncbi.nlm.nih.gov/pubmed/21093696

Evaluation of a New; Rapid Test for Detecting HCV Infection; Suitable for Use with Blood or Oral Fluid. Lee SR, Kardos KW, Schiff E, et al. J Virol Methods. 2010 Dec 20. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21182871

Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. Friedland G. J Acquir Immune Defic Syndr. 2010 Dec 1;55 Suppl 1:S37-42.
http://www.ncbi.nlm.nih.gov/pubmed/21045598

Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. Swan D, Long J, Carr O, et al. AIDS Patient Care STDS. 2010 Dec;24(12):753-62.
http://www.ncbi.nlm.nih.gov/pubmed/21138381

Effects of recognizing depression with a standardized questionnaire (CES-D) versus patient reporting of depression after a single-standardized question on the outcomes of treatment for hepatitis C with pegylated interferon-α-2b and ribavirin. Phillips FH, Prebis M, Grumbeck C, Hale T, Cubillas R, Brown GR. Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1435-42.
http://www.ncbi.nlm.nih.gov/pubmed/20802340

Liver Cancer

Increasing Prevalence of HCC and Cirrhosis in Patients with Chronic Hepatitis C Virus Infection. Kanwal F, Hoang T, Kramer JR, et al. Gastroenterology. 2010 Dec 21. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21184757

Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. Kumada T, Toyoda H, Kiriyama S, et al. Gastroenterol. 2010 Dec 7. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21132575

Correlation between clinical characteristics, survival and genetic alterations in patients with hepatocellular carcinoma from Saudi Arabia. Al-Qahtani A, Al-Hazzani T, Al-Hussain T, et al. Cancer Genet Cytogenet. 2010 Dec;203(2):269-77.http://www.ncbi.nlm.nih.gov/pubmed/21156243

Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
Hagihara H, Nouso K, Kobayashi Y,et al. Int J Clin Oncol. 2010 Dec 9. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21152943

Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges.
Bouchard MJ, Navas-Martin S. Cancer Lett. 2010 Dec 17. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21168955

Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Arano T, Nakagawa H, Tateishi R, et al. Int J Cancer. 2010 Dec 17. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21170963